---
title: Modern individualized diagnostics and treatment of non-small cell lung cancer
date: '2024-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38376521/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240220170715&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Approximately one half of patients with non-small cell lung cancer (NSCLC)
  are diagnosed at resectable tumor stages (I-IIIA), which can potentially be curatively
  treated. In the early tumor stages (tumor diameter ≤2 cm) sublobar resection (segmentectomy
  or atypical wedge resection) leads to a 5‑year long-term survival comparable to
  lobectomy. The use of immunotherapy, especially within the framework of neoadjuvant
  treatment, is anticipated to change the surgical treatment of NSCLC in the ...
disable_comments: true
---
Approximately one half of patients with non-small cell lung cancer (NSCLC) are diagnosed at resectable tumor stages (I-IIIA), which can potentially be curatively treated. In the early tumor stages (tumor diameter ≤2 cm) sublobar resection (segmentectomy or atypical wedge resection) leads to a 5‑year long-term survival comparable to lobectomy. The use of immunotherapy, especially within the framework of neoadjuvant treatment, is anticipated to change the surgical treatment of NSCLC in the ...